Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IGKV1D-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1D-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1D-39 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1D-16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1D-16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1D-16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1D-17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1D-17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1D-17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1D-33 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1D-33 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1D-33 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1D-37 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1D-37 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1D-37 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1D-13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1D-13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1D-13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1D-12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1D-12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1D-12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGKV1-33 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGKV1-33 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV1-33 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →